Get the Daily Brief
Latest Biotech News
Servier to buy Day One for $2.5bn—rare cancer pipeline expands
Servier agreed to acquire Day One Biopharmaceuticals in a transaction valued at about $2.5 billion, paying $21.50 per share in cash, the companies said. Servier said the acquisition will add Day...
BioNTech founders to exit—new mRNA spinout incoming
BioNTech confirmed that co‑founders Uğur Şahin and Özlem Türeci will leave the company by year‑end to launch a new venture focused on next‑generation mRNA therapeutics. BioNTech said it will grant...
Bristol Myers’ CELMoD mezigdomide clears Phase 3—myeloma program advances
Bristol Myers Squibb announced that mezigdomide, an oral CELMoD protein‑degrading agent, met its primary endpoint in a late‑stage trial for relapsed/refractory multiple myeloma, showing a...
Ipsen withdraws Tazverik after safety signal—market removal implemented
Ipsen announced an immediate market withdrawal of tazemetostat (Tazverik) following detection of secondary hematologic malignancies in a confirmatory trial, the company said. The decision halts...
Blackstone backs Teva with up to $400m—IBD antibody gets fuel
Teva Pharmaceuticals struck a growth capital deal with Blackstone Life Sciences for up to $400 million to advance duvakitug, a TL1A‑blocking monoclonal antibody in Phase III for inflammatory bowel...
Verily and Samsung link smartwatch data to trials—wearables move into endpoints
Verily and Samsung announced a partnership to integrate Galaxy smartwatch data into Verily’s Pre platform, creating an end‑to‑end system for deploying wearables in clinical studies and analyzing...
In vivo CAR T approaches escalate—industry bets on off‑the‑shelf engineering
A review of in vivo CAR T strategies highlights accelerating investment and early clinical signals as companies race to reprogram T cells inside the patient rather than ex vivo. Integrated viral...
AI tool accelerates synthetic routes—cheminformatics meets bench chemistry
Researchers unveiled an AI‑driven platform that streamlines chemical synthesis planning and accelerates drug candidate generation, reducing iterative medicinal chemistry cycles. The tool automates...
Teva Taps Blackstone for $400m Push on Late‑Stage IBD Antibody
Teva Pharmaceuticals signed a growth‑capital agreement with Blackstone Life Sciences that could deliver up to $400 million over four years to accelerate development of duvakitug, a monoclonal...
Vertex’s Kidney Drug Halves Key IgA Nephropathy Marker in Phase 3
Vertex reported Phase 3 data showing its acquired therapy cut a key biomarker for IgA nephropathy by roughly 50%, mirroring or exceeding results from peers and positioning the program as a...
Ferritin bridge strengthens CAR‑T engagement – a non‑genetic fix for relapse
Researchers at the Institute of Process Engineering, Chinese Academy of Sciences, introduced a ferritin‑based aggregation cell engager (FACE) that augments CAR‑T cell avidity without...
Xenon’s epilepsy pill slashes seizures — phase 3 blowout
Xenon Pharmaceuticals announced Phase 3 X‑Tole2 results showing azetukalner reduced focal‑onset seizure frequency by 53.2% at the 25 mg dose versus placebo—an effect the company characterized as...
Roche’s oral SERD fails first‑line test — ripples across the oral SERD field
Roche’s Phase 3 PersevERA study of the oral SERD giredestrant missed its primary progression‑free survival endpoint in the first‑line ER‑positive, HER2‑negative breast cancer setting, the company...
Ipsen pulls Tazverik after trial monitors spot secondary blood cancers
Ipsen announced a voluntary withdrawal of Tazverik (tazemetostat) from the market and halted ongoing clinical studies after an independent data monitoring committee identified cases of secondary...
Verily and Samsung link wearables to trials — AI also matches doctors to studies
Verily and Samsung agreed to integrate Galaxy smartwatch data into Verily’s Pre platform to provide an end‑to‑end system for deploying wearables in clinical research, collecting passive...
Novo, Hims strike deal to curb compounding and widen GLP‑1 access
Novo Nordisk and telehealth firm Hims & Hers reached an agreement under which Novo will supply its GLP‑1 medicines through Hims at the same prices other telehealth providers offer, and Hims will...
In‑vivo CAR‑T and predictive biomarkers: two fronts for widening cell therapy access
Industry attention is splitting between in‑vivo CAR‑T strategies that aim to reprogram T cells inside patients and biomarker research that predicts ex‑vivo CAR‑T outcomes. In‑vivo CAR‑T...
WHO to recommend near‑patient molecular TB tests and tongue swabs
The World Health Organization will issue updated TB diagnostics guidance recommending a new class of near‑point‑of‑care molecular tests with lower unit costs, use of tongue swab sampling for...
Vertex kidney drug hits Phase 3 goal – best‑in‑class hopes rise
Vertex reported positive late‑stage results for a drug it acquired, showing a roughly 50% reduction in a key biomarker for IgA nephropathy in a Phase 3 study. The company said the data match or...
Xenon’s epilepsy pill crushes Phase 3 target: seizure rates halved
Xenon Pharmaceuticals announced Phase 3 X‑Tole2 results for azetukalner showing a 53.2% placebo‑adjusted reduction in focal onset seizure frequency at the 25 mg dose and strong tolerability at the...